Skip to main content
Journal cover image

Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.

Publication ,  Journal Article
Baroni, LV; Sundaresan, L; Heled, A; Coltin, H; Pajtler, KW; Lin, T; Merchant, TE; McLendon, R; Faria, C; Buntine, M; White, CL; Pfister, SM ...
Published in: Neuro Oncol
August 2, 2021

BACKGROUND: Within PF-EPN-A, 1q gain is a marker of poor prognosis, however, it is unclear if within PF-EPN-A additional cytogenetic events exist which can refine risk stratification. METHODS: Five independent non-overlapping cohorts of PF-EPN-A were analyzed applying genome-wide methylation arrays for chromosomal and clinical variables predictive of survival. RESULTS: Across all cohorts, 663 PF-EPN-A were identified. The most common broad copy number event was 1q gain (18.9%), followed by 6q loss (8.6%), 9p gain (6.5%), and 22q loss (6.8%). Within 1q gain tumors, there was significant enrichment for 6q loss (17.7%), 10q loss (16.9%), and 16q loss (15.3%). The 5-year progression-free survival (PFS) was strikingly worse in those patients with 6q loss, with a 5-year PFS of 50% (95% CI 45%-55%) for balanced tumors, compared with 32% (95% CI 24%-44%) for 1q gain only, 7.3% (95% CI 2.0%-27%) for 6q loss only and 0 for both 1q gain and 6q loss (P = 1.65 × 10-13). After accounting for treatment, 6q loss remained the most significant independent predictor of survival in PF-EPN-A but is not in PF-EPN-B. Distant relapses were more common in 1q gain irrespective of 6q loss. RNA sequencing comparing 6q loss to 6q balanced PF-EPN-A suggests that 6q loss forms a biologically distinct group. CONCLUSIONS: We have identified an ultra high-risk PF-EPN-A ependymoma subgroup, which can be reliably ascertained using cytogenetic markers in routine clinical use. A change in treatment paradigm is urgently needed for this particular subset of PF-EPN-A where novel therapies should be prioritized for upfront therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

August 2, 2021

Volume

23

Issue

8

Start / End Page

1360 / 1370

Location

England

Related Subject Headings

  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Microarray Analysis
  • Humans
  • Ependymoma
  • Chromosomes
  • Chromosome Aberrations
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baroni, L. V., Sundaresan, L., Heled, A., Coltin, H., Pajtler, K. W., Lin, T., … Ramaswamy, V. (2021). Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol, 23(8), 1360–1370. https://doi.org/10.1093/neuonc/noab034
Baroni, Lorena V., Lakshmikirupa Sundaresan, Ayala Heled, Hallie Coltin, Kristian W. Pajtler, Tong Lin, Thomas E. Merchant, et al. “Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.Neuro Oncol 23, no. 8 (August 2, 2021): 1360–70. https://doi.org/10.1093/neuonc/noab034.
Baroni LV, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021 Aug 2;23(8):1360–70.
Baroni, Lorena V., et al. “Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.Neuro Oncol, vol. 23, no. 8, Aug. 2021, pp. 1360–70. Pubmed, doi:10.1093/neuonc/noab034.
Baroni LV, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T, Merchant TE, McLendon R, Faria C, Buntine M, White CL, Pfister SM, Gilbert MR, Armstrong TS, Bouffet E, Kumar S, Taylor MD, Aldape KD, Ellison DW, Gottardo NG, Kool M, Korshunov A, Hansford JR, Ramaswamy V. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021 Aug 2;23(8):1360–1370.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

August 2, 2021

Volume

23

Issue

8

Start / End Page

1360 / 1370

Location

England

Related Subject Headings

  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Microarray Analysis
  • Humans
  • Ependymoma
  • Chromosomes
  • Chromosome Aberrations
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences